高级检索
当前位置: 首页 > 详情页

miR-630 functions as a tumor oncogene in renal cell carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Univ Engn, Affiliated Hosp, Dept Urol, Handan, Hebei, Peoples R China [2]Hebei Med Univ, Hosp 4, Dept Surg, Shijiazhuang, Hebei, Peoples R China [3]Handan Cent Hosp, Dept Neurol, Handan, Hebei, Peoples R China [4]Hebei Med Univ, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China
出处:
ISSN:

关键词: renal cell carcinoma miR-630 proliferation migration invasion

摘要:
Introduction: MicroRNAs (miRNAs) are non-coding RNAs that regulate multiple cell processes during cancer progression. Renal cell carcinoma (RCC) is a malignancy with a poor prognosis. In this study, we aimed to investigate the roles of miR-630 in RCC progression. Material and methods: Expression of miR-630 was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) in four renal cancer cell lines (786-O, ACHN, Caki-1, and Caki-2) and one normal human proximal tubule epithelial cell line (HK-2). Next, miR-630 inhibitor was used to inhibit miR-630 expression in 786-O cells. Finally, its effects on cell proliferation, apoptosis, migration, and invasion were evaluated. Results: The expression level of miR-630 was higher in renal cancer cell lines 786-O, ACHN, Caki-1, and Caki-2 than that in the normal renal cell line HK-2 (p < 0.05). Furthermore, a proliferation assay, apoptosis assay, migration assay and invasion assay were performed, and the results showed that down-regulation of miR-630 expression by miR-630 inhibitor significantly inhibited cell proliferation, migration, and invasion, which meanwhile induced cell apoptosis of the renal cancer cell line 786-O. Conclusions: This is the first time that miR-630 expression has been shown to be associated with renal cancer progression, and down-regulation of miR-630 can inhibit tumor progression, which provides a potential therapeutic target for renal cancer treatment.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 3 区 医学:内科
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 医学:内科
JCR分区:
出版当年[2016]版:
Q2 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Hebei Univ Engn, Affiliated Hosp, Dept Urol, Handan, Hebei, Peoples R China [2]Hebei Med Univ, Hosp 4, Dept Surg, Shijiazhuang, Hebei, Peoples R China
通讯作者:
通讯机构: [2]Hebei Med Univ, Hosp 4, Dept Surg, Shijiazhuang, Hebei, Peoples R China [*1]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei 050011, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15100 今日访问量:0 总访问量:960 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号